|
Whither
high-dose chemotherapy in breast cancer?
A phase
II trial of docetaxel for peripheral blood stem cell mobilization
for patients with breast cancer and ovarian cancerL
.Laport
GG, Fleming GF, Waggoner S, Zimmerman TM, Grinblatt DL, Williams
SF.
A
novel pharmacological action of ET-1 to prevent the cytotoxicity
of doxorubicin in cardiomyocytes.
Suzuki T, Miyauchi T. Am J Physiol Regul Integr Comp Physiol.
2001;280:R1399-406.
Extracellularly
tumor-activated prodrugs for the selective chemotherapy of
cancer: application to doxorubicin and preliminary in vitro
and in vivo studies.
Trouet
A, Passioukov A, Van derpoorten K, et al. Cancer Res. 2001;61:2843-6.
Gene
expression and amplification in breast carcinoma cells with
intrinsic and acquired doxorubicin resistance.
Turton NJ, Judah DJ, Riley J, et al. Oncogene. 2001;20:1300-6.
Reduction
of Paclitaxel-induced Peripheral Neuropathy with Glutamine.
Vahdat
L, Papadopoulos K, Lange D, et al. Clin Cancer Res. 2001;7:1192-1197.
Reduction
of Paclitaxel-induced Peripheral Neuropathy with Glutamine.
Vahdat
L, Papadopoulos K, Lange D, et al. Clin Cancer Res. 2001;7:1192-1197.
A
new prodrug of paclitaxel: synthesis of Protaxel
Seligson AL, Terry RC, Bressi JC, Douglass III JG, Sovak M..
Anticancer Drugs. 2001;12:305-13.
Hyperthermic
enhancement of the apoptotic and antiproliferative activities
of paclitaxel.
Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M.
Pharmacology. 2001;62:208-12.
Benefit
of a high-dose epirubicin regimen in adjuvant chemotherapy
for node-positive breast cancer patients with poor prognostic
factors: 5-year follow-up results of French adjuvant study
group 05 randomized trial.
Adenis
A, Bonneterre J, Bonneterre ME, et al. Journal
of Clinical Oncology. 19(3):602-611, 2001 Feb 1.
A
critique of the eleven randomised trials of high-dose chemotherapy
for breast cancer [Review].
Antman KH. European Journal of Cancer. 37(2):173-179, 2001
Jan.
Infectious
complications the year after autologous bone marrow transplantation
or peripheral stem cell transplantation for treatment of breast
cancer.
Barton
TD, Collis T, Stadtmauer E, Schuster MG. Clinical
Infectious Diseases. 32(3):391-395, 2001 Feb 1.
High-dose
thiotepa and melphalan with hemopoietic progenitor support
following induction therapy with epirubicin-paclitaxel-containing
regimens in metastatic breast cancer (MBC).
Bengala
C, Pazzagli I, Innocenti F, et al. Annals
of Oncology. 12(1):69-74, 2001 Jan.
Low
infectious morbidity after intensive chemotherapy and autologous
peripheral blood progenitor cell transplantation in the outpatient
setting for women with breast cancer.
Chandrasekar PH, Abraham OC, Klein J, et al. Clinical Infectious
Diseases. 32(4):546-551, 2001 Feb 15.
A
short course of induction chemotherapy followed by two cycles
of high-dose chemotherapy with stem cell rescue for chemotherapy
naive metastatic breast cancer.
Elias AD, Richardson P, Avigan D, et al. Bone Marrow Transplantation.
27(3):269-278, 2001 Feb.
Use
of granulocyte colony-stimulating factor after high-dose chemotherapy
and autologous peripheral blood stem cell transplantation
- What is the optimal timing?
Ener RA, Meglathery SB, Cuhaci B, et al. American Journal
of Clinical Oncology-Cancer Clinical Trials. 24(1):19-25,
2001 Feb.
Hematopoietic
recovery of ex vivo perfusion culture expanded bone marrow
and unexpanded peripheral blood progenitors after myeloablative
chemotherapy.
Engelhardt
M, Douville J, Behringer D, et al. Bone
Marrow Transplantation. 27(3):249-259, 2001 Feb.
Intensification
of adjuvant chemotherapy: 5-year results of a randomized trial
comparing conventional doxorubicin and cyclophosphamide with
high-dose mitoxantrone and cyclophosphamide with filgrastim
in operable breast cancer with 10 or more involved axillary
nodes.
Fumoleau
P, Chauvin F, Namer M, et al. Journal
of Clinical Oncology. 19(3):612-620, 2001 Feb 1.
A
randomized trial of amifostine in patients with high-dose
VIC chemotherapy plus autologous blood stem cell transplanation.
Hartmann JT, von Vangerow A, Fels LM, et al. British Journal
of Cancer. 84(3):313-320, 2001 Feb 2.
Population
pharmacokinetics of thioTEPA and its active metabolite TEPA
in patients undergoing high-dose chemotherapy.
Huitema ADR, Mathot RAA, Tibben MM, Schellens JHM, Rodenhuis
S, Beijnen JH. British Journal of Clinical Pharmacology. 51(1):61-70,
2001 Jan.
Modulation
of graft-versus-tumor effects in a murine allogeneic bone
marrow transplantation model by tumor-derived transforming
growth factor-beta 1.
Kummar S, Ishii A, Yang HK, Venzon DJ, Kim SJ, Gress RE. Biology
of Blood & Marrow Transplantation. 7(1):25-30, 2001.
Whither
high-dose chemotherapy in breast cancer? [Review].
Mayer A, Earl H. Breast Cancer Research. 3(1):8-10, 2001.
The
pharmacokinetics and pharmacodynamics of high-dose paclitaxel
monotherapy (825 mg/m(2) continuous infusion over 24 h) with
hematopoietic support in women with metastatic breast cancer.
Papadopoulos
KP, Egorin MJ, Huang M, et al. Cancer
Chemotherapy & Pharmacology. 47(1):45-50, 2001 Jan.
High-dose
chemotherapy in breast cancer - interpretation of the randomized
trials.
Rodenhuis S. Anti-Cancer Drugs. 12(2):85-88, 2001 Feb.
Prognostic
significance of the immunocytochemical detection of contaminating
tumor cells (CTC) in apheresis products of patients with high-risk
breast cancer treated with high-dose chemotherapy and stem
cell transplantation.
Solano
C, Badia B, Lluch A, et al. Bone
Marrow Transplantation. 27(3):287-293, 2001 Feb.
Pilot
trial of interleukin-1 with granulocyte colony-stimulating
factor for the mobilization of progenitor cells in advanced
breast cancer patients undergoing high-dose chemotherapy:
Expansion of immune effectors within the stem-cell graft and
post-stem-cell infusion.
Sosman JA, Stiff P, Moss SM, et al. Journal of Clinical Oncology.
19(3):634-644, 2001 Feb 1.
Preoperative
high-dose chemotherapy with peripheral blood stem cell support
as a primary management of locally advanced breast cancer.
Wang
X, Tang J, Wu J, et al. Bone
Marrow Transplantation. 27(3):345-346, 2001 Feb.
Clinical
Impacts of Tumor Cell Contamination of Hematopoietic Stem
Cell Products in Metastatic Breast Cancer Patients undergoing
Autologous Peripheral Blood Stem Cell Transplantation: Multicenter
Trial.
Ahn
MJ, Noh YH, Lee YS, et al. J
Korean Med Sci. 2001;16:175-82.
Randomized
trials of high dose chemotherapy for breast cancer.
Antman KH. Biochim Biophys Acta. 2001;1471:M89-98.
Kinetics
of PBPC mobilization by cyclophosphamide, as compared with
that by epirubicin/paclitaxel followed by G-CSF support: implications
for optimal timing of PBPC harvest.
Dettke M, Greinix HT, Kalhs P, Kuhrer I, Worel N, Hocker P.
Transfusion. 2001;41:681-6.
A
phase II trial of docetaxel for peripheral blood stem cell
mobilization for patients with breast cancer and ovarian cancer.
Laport GG, Fleming GF, Waggoner S, Zimmerman TM, Grinblatt
DL, Williams SF. Bone Marrow Transplant. 2001;27:677-81.
|
